Related Experiment Videos
Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy
G S Robinson1, E A Pierce, S L Rook
1Hybridon, Inc., Worcester, MA 01605, USA.
Abstract:
Diseases characterized by retinal neovascularization are among the principal causes of visual loss worldwide. The hypoxia-stimulated expression of vascular endothelial growth factor (VEGF) has been implicated in the proliferation of new blood vessels. We have investigated the use of antisense phosphorothioate oligodeoxynucleotides against murine VEGF to inhibit retinal neovascularization and VEGF synthesis in a murine model of proliferative retinopathy. Intravitreal injections of two different antisense phosphorothioate oligodeoxynucleotides prior to the onset of proliferative retinopathy reduced new blood vessel growth a mean of 25 and 31% compared with controls. This inhibition was dependent on the concentration of antisense phosphorothioate oligodeoxynucleotides and resulted in a 40-66% reduction in the level of VEGF protein, as determined by Western blot analysis. Control (sense, nonspecific) phosphorothioate oligodeoxynucleotides did not cause a significant reduction in retinal neovascularization or VEGF protein levels. These data further establish a fundamental role for VEGF expression in ischemia-induced proliferative retinopathies and a potential therapeutic use for antisense phosphorothioate oligodeoxynucleotides.
Insights
Antisense oligodeoxynucleotides targeting vascular endothelial growth factor (VEGF) effectively inhibited retinal neovascularization in a mouse model. This approach shows potential for treating vision loss caused by new blood vessel growth.
Area of Science:
- Ophthalmology
- Molecular Biology
- Genetics
Background:
- Retinal neovascularization is a major cause of vision loss globally.
- Vascular Endothelial Growth Factor (VEGF) drives new blood vessel formation in response to hypoxia.
- Ischemia-induced proliferative retinopathies involve pathological neovascularization.
Purpose of the Study:
- To investigate the efficacy of antisense phosphorothioate oligodeoxynucleotides against murine VEGF.
- To inhibit retinal neovascularization and VEGF synthesis in a mouse model of proliferative retinopathy.
- To evaluate the therapeutic potential of antisense technology for vision-threatening conditions.
Main Methods:
- Utilized a murine model of proliferative retinopathy.
- Administered intravitreal injections of antisense phosphorothioate oligodeoxynucleotides targeting VEGF.
- Quantified new blood vessel growth and VEGF protein levels via Western blot analysis.
- Compared effects of antisense, sense, and non-specific control oligodeoxynucleotides.
Main Results:
- Antisense oligodeoxynucleotides significantly reduced new blood vessel growth by 25-31%.
- VEGF protein levels decreased by 40-66% following antisense treatment.
- Inhibition was dose-dependent.
- Control oligodeoxynucleotides showed no significant effect.
Conclusions:
- VEGF plays a critical role in ischemia-induced proliferative retinopathies.
- Antisense phosphorothioate oligodeoxynucleotides demonstrate therapeutic potential for inhibiting retinal neovascularization.
- This study supports antisense technology as a viable strategy for treating related visual impairments.